# The Line Is Drawn by Surgery

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/the-line-is-drawn-by-surgery

> A meta-regression found study arms with greater average weight loss had higher rates of fatty liver disease resolving. The authors say plainly it cannot establish cause, and a handful of surgical arms are pulling the line.

## Key points

- Across six trials, arms with more average weight loss had more disease resolution.
- It relates GROUP AVERAGES, not individuals. The authors name the ecological fallacy themselves.
- And the slope is 'strongly influenced by a small number of high-weight-loss SURGICAL arms'.
- So the question people ask (will more weight loss on my drug help my liver more?) is barely addressed.
- Contrast: for the heart, benefit was largely INDEPENDENT of weight loss, in 17,604 individuals.

Does losing more weight repair more liver damage? A meta-regression across six randomized trials found that study arms with greater average weight loss had higher rates of fatty liver disease resolving.[1] The authors then say plainly that this **cannot establish cause**, and that the relationship is largely driven by a handful of bariatric surgery arms.

## What was compared

Six randomized trials covering 1,379 people, testing tirzepatide, semaglutide, sleeve gastrectomy and gastric bypass (plus, in one trial each, an endoscopic procedure and a structured diet program) against placebo or standard care, with liver biopsy outcomes: resolution of the disease, and improvement in fibrosis.

Tirzepatide, semaglutide and both surgeries beat their comparators for disease resolution. Beyond that, the reviewers note the network was **weakly connected and largely placebo-anchored**. Almost every trial compared its drug against placebo rather than against another drug, so indirect comparisons between the treatments were imprecise.

## The regression, and what it is a regression on

> **This analysis relates the *average* weight loss in each study arm to the *rate* of liver improvement in that same arm.** It is a relationship between group summaries. It does not observe individual people, and an association between group averages does not establish one between individuals. The error has a name, the ecological fallacy, and the authors raise it themselves.

A worked example makes it concrete. Suppose surgical arms average 30% weight loss and 60% disease resolution, while drug arms average 12% and 30%. Plotting those four numbers gives a convincing line. But it is entirely possible that within each arm, the individuals who lost the most were *not* the ones whose livers improved most. Group-level data cannot tell you.

> A line through four group averages is not a dose-response relationship.

## And the line is being pulled by surgery

The paper states that the associations were *strongly influenced by a small number of high-weight-loss surgical arms*. Those arms sit far to the right of everything else on the weight axis, and points at the extreme of a range exert the most leverage on a fitted line.

That means most of the apparent relationship is the gap between **drug arms and surgical arms**, not a gradient within either. And bariatric surgery differs from a drug in a great deal besides the amount of weight it removes: how fast the weight comes off, what happens to gut hormones, how eating changes permanently, who is selected for it.

> **The question people want answered, whether losing more weight on this drug will improve their liver more, is barely addressed.** It would require the gradient *within* drug arms, in individuals, and this design cannot supply it.

## How this sits beside the heart evidence

There is an instructive contrast here. For cardiovascular outcomes, a prespecified analysis of 17,604 individuals found the benefit **largely independent of weight loss**: no linear relationship between weight lost and later events, and only about a third mediated through waist circumference. That is in [losing weight predicted more heart attacks](https://glpwatchdog.org/research/losing-weight-predicted-more-heart-attacks).

For the liver, weight loss does appear to track improvement, but at the group level, in an analysis its authors call exploratory.

Both can be true. The liver is directly loaded by fat stored in it, and removing that fat is a plausible mechanical route to improvement in a way it is not for an artery. But the strength of evidence behind those two statements is very different: 17,604 individuals analyzed prospectively, against arm-level averages from six trials of 1,379 people, and the difference in what they can support is larger than the difference in what they found.

For what the liver evidence does establish, see [GLP-1s and fatty liver](https://glpwatchdog.org/research/glp1-and-fatty-liver-mash); for a trial that measured the tests rather than the tissue, [a trial about the measuring instrument](https://glpwatchdog.org/research/a-trial-about-the-measuring-instrument).

## What the authors ask for

Their conclusion is that the limited evidence base, sparse network and ecological nature of the analysis preclude causal inference, that the findings should be considered exploratory and hypothesis-generating, and that adequately powered head-to-head trials are needed.

The paper describes its own limits accurately, and every caveat in this article comes from the authors’ own text. The risk lies not in the analysis but in what happens to “more weight loss, more liver improvement” once it leaves the paper.

## Frequently asked questions

### Does losing more weight improve fatty liver disease more?

Across six randomized trials, study arms with greater average weight loss had higher rates of disease resolution and fibrosis improvement. The authors state this cannot establish cause, because it relates group averages rather than individuals.

### Why does that distinction matter?

An association between arm averages does not establish one within individuals; assuming it does is the ecological fallacy. Within any given arm, the people who lost the most weight may not be the ones whose livers improved most, and group-level data cannot show it either way.

### What is driving the relationship?

The authors say it was strongly influenced by a small number of high-weight-loss surgical arms, which sit at the extreme of the range and exert the most leverage on a fitted line. So most of it is the gap between drug arms and surgery, not a gradient within either.

### Do these drugs help fatty liver disease?

Tirzepatide, semaglutide and both bariatric procedures beat placebo or standard care for disease resolution in these trials. What is not established is whether more weight loss on a drug produces proportionally more liver improvement.

### Why does weight track liver improvement but not heart outcomes?

It may be that the liver is directly loaded by fat stored in it, in a way an artery is not. But the evidence differs enormously in strength: 17,604 individuals analyzed prospectively for the heart question, against arm-level averages from six trials for the liver.

## References

1. Monami M, Belluzzi A, Buscemi S, et al. Weight Loss as a Determinant of Histological Improvement in Metabolic Dysfunction-Associated Steatotic Liver Disease in People With Obesity. A Systematic Review and Network Meta-Analysis of Randomised Clinical Trials. Diabetes, Obesity and Metabolism. 2026. PMID: 41804193. https://pubmed.ncbi.nlm.nih.gov/41804193/

---

Cite as: GLP Watchdog, Nora Bissett, "The Line Is Drawn by Surgery", published 2026-08-20, updated 2026-10-27. https://glpwatchdog.org/research/the-line-is-drawn-by-surgery

Canonical HTML page: https://glpwatchdog.org/research/the-line-is-drawn-by-surgery

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
